Accretion Nutraveda Ltd
- Market cap
- ₹ 210 Cr.
- P/E
- 41.4x
- P/B
- 6.18x
- 52-week range
- 150.1 – 313
- ROE
- 25%
- ROCE
- 27.7%
- Dividend yield
- 0%
- Debt / equity
- 0.12
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Accretion Nutraveda Limited is an India-based healthcare focused company. The Company is engaged in the manufacturing and sale of pharmaceutical products. It is engaged in the manufacturing of Ayurvedic and Nutraceutical products across multiple dosage forms, which include tablets, capsules, oral liquids, oral powders, external preparations, and oils. Its product portfolio includes tablets such as film-coated and chewable forms, intended for applications related to liver care, gynecological care, bone and joint health, and respiratory support. It also manufactures capsules directed towards liver detoxification, women’s health, and cognitive support. Its oral liquid products include syrups, suspensions, tonics, and traditional decoctions, formulated for paediatric and geriatric applications. It also produces traditional Ayurvedic powders, known as churans, for digestive health, medicated Ayurvedic oils used in musculoskeletal and dermatological treatments.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Accretion Nutraveda Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)41.4 against a typical 34: pricier than most peers (1st = cheapest).136th of 220
- Share price, 3 months+2.1% against a typical −0.5%.85th of 200
- Size₹ 210 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).115th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 11 | 14 | 20 |
| Expenses | 8 | 11 | 16 |
| Operating Profit | 3 | 3 | 4 |
| OPM % | 23.8% | 23.5% | 18.2% |
| Other Income | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 3 |
| Tax % | 22.2% | 18.5% | 18.5% |
| Net Profit | 2 | 2 | 3 |
| EPS in Rs | 35.32 | 4.38 | 3.72 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 127%
- TTM
- 110%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 163%
- TTM
- 103%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 35%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Accretion Nutraveda Ltd | ₹ 290.00 | ₹ 210 Cr. | 41.4x | 6.2x | 25% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 35.7x | 5.2x | — | 19.8% |
| Divi's Laboratories | ₹ 8,950.00 | ₹ 2,37,594 Cr. | 92.7x | 14.5x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,660.00 | ₹ 1,77,245 Cr. | 72.9x | 19.3x | — | 13.7% |
| Laurus Labs | ₹ 1,970.00 | ₹ 1,06,442 Cr. | 120.1x | 20.2x | — | 15% |
| Cipla | ₹ 1,338.00 | ₹ 1,08,091 Cr. | 26.7x | 3.2x | — | 11.9% |
Management
- Paraskumar Vinubhai Parmar
- Chief Financial Officer, Executive Director
- Payal Hareshbhai Kotadiya
- Company Secretary, Compliance Officer
- Mayur Popatlal Sojitra
- Managing Director, Executive Director
- Ankurkumar Shantilal Patel
- Whole Time Director
- Vivek Ashok Kumar Patel
- Non-Independent Non-Executive Director
- Harshad Nanubhai Rathod
- Non-Independent Non-Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.